[Huntington disease].
Doi
Hiroshi
H
Department of Neurology, Yokohama City University School of Medicine.
Kuroiwa
Yoshiyuki
Y
Doi
Hiroshi
H
Nukina
Nobuyuki
N
D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D037001:Directive Counseling; D005799:Genes, Dominant; D006801:Humans; D006816:Huntington Disease / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D010455:Peptides / Q000737:chemistry; D012015:Reference Standards; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D018911:Trinucleotide Repeats
D018726:Anti-Dyskinesia Agents; D014150:Antipsychotic Agents; D010455:Peptides; D017367:Selective Serotonin Reuptake Inhibitors; C097188:polyglutamine